Obesity and atrial fibrillation: mechanisms of occurence and current treatment guidelines


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The role of obesity as a factor of atrial fibrillation (AF) is currently discussed nowadays. Several mechanisms of the influence of excessive body weight at AF development are described in the literature: the occurrence of arterial hypertension, insulin resistance, and dyslipidemia. The molecular mechanisms of AF in obese patients include systemic inflammation. Management tactics for obese patients with AF include 3 main directions - anticoagulant therapy in case of increased risk of thromboembolic complications, control of arrhythmia symptoms, treatment of comorbidities and correction of risk factors. There are two main strategies in the treatment of AF: rhythm control and ventricular rate control. Stabilizing treatment of AF paroxysms in obesity is differentiated according to the stability of haemodynamic parameters. In patients with stable haemodynamics, IC and class III medicaments are recommended for sinus rhythm restoration in AF paroxysms.

Full Text

Restricted Access

About the authors

Aida I. Tarzimanova

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

Email: tarzimanova@mail.ru
Dr. med. habil., professor of the Department of faculty therapy No. 2 119048, Moscow, 24 Efremova Str

References

  1. Российское кардиологическое общество, Российское научное медицинское общество терапевтов, Антигипертензивная лига, организация содействия развитию догоспитальной медицины «Амбулаторный врач», Ассоциация клинических фармакологов. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации) / под ред. Шляхто Е.В., Недогода С.В., Конради А.О. СПб. 2017; 164 с. Доступ: https://www.scardio.ru/content/Guidelines/project/Ozhirenie_klin_rek_proekt.pdf (дата обращения - 01.09.2022).
  2. Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020; ehaa612. https://dx.doi.org/10.1093/eurheartj/ehaa612.
  3. Goudis C.A., Korantzopoulos P., Ntalas I.V. et al. Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and links. J Cardiol. 2015; 66(5): 361-69. https://dx.doi.org/10.1016/j.jjcc.2015.04.002.
  4. Kotsis V., Stabouli S., Papakatsika S. et al. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010; 33(5): 386-93. https://dx.doi.org/10.1038/hr.2010.9.
  5. Ogunsua A.A., Shaikh A.Y., Ahmed M., McManus D.D. Atrial fibrillation and hypertension: Mechanistic, epidemiologic, and treatment parallels. Methodist Debakey Cardiovasc J. 2015; 11(4): 228-34. https://dx.doi.org/10.14797/mdcj-11-4-228.
  6. Yang T., Yang P., Roden D.M., Darbar D. Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm. 2010; 7(9): 1246-52. https://dx.doi.org/10.1016/j.hrthm.2010.05.032.
  7. Lumeng C.N., Del Proposto J.B., Westcott D.J. et al. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes. 2008; 57(12): 3239-46. https://dx.doi.org/10.2337/db08-0872.
  8. Daugherty S.L., Powers J.D., Magid D.J. et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125(13): 1635-42. https://dx.doi.org/10.1161/CIRCULATIONAHA.111.068064.
  9. Goudis C., Korantzopoulos P., Ntalas I. Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies.Int J Cardiol. 2015; 184: 617-22. https://dx.doi.org/10.1016/j.ijcard.2015.03.052.
  10. Goudis C.A., Korantzopoulos P., Ntalas I.V. et al. Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and links. J Cardiol. 2015; 66(5): 361-69. https://dx.doi.org/10.1016/j.jjcc.2015.04.002.
  11. Abed H.S., Wittert G.A. Obesity and atrial fibrillation. Obes Rev. 2013; 14(11): 929-38. https://dx.doi.org/10.1111/obr.12056.
  12. Abe I., Teshima Y., Kondo H. Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation. Heart Rhythm. 2018; 15(11): 1717-27. https://dx.doi.org/10.1016/j.hrthm.2018.06.025.
  13. Mahajan R., Lau D.H., Brooks A.G. et al. Electrophysiological, electroanatomical and structural remodeling of the atria as a consequence of sustained obesity. J Am Coll Cardiol. 2015; 66(1): 1-11. https://dx.doi.org/10.1016/j.jacc.2015.04.058.
  14. Fox C.S., Gona P., Hoffmann U. et al. Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: The Framingham Heart Study. Circulation. 2009; 119(12): 1586-91. https://dx.doi.org/10.1161/CIRCULATIONAHA.108.828970.
  15. Hu Y.F., Chen Y.J., Lin Y.J. et al. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015; 12(4): 230-43. https://dx.doi.org/10.1038/nrcardio.2015.2.
  16. Kondo H., Abe I., Gotoh K. et al.Interleukin 10 treatment ameliorates high-fat diet-induced inflammatory atrial remodeling and fibrillation. Circ Arrhythm Electrophysiol. 2018; 11(5): e006040. https://dx.doi.org/10.1161/CIRCEP.117.006040.
  17. Драпкина О.М., Николаева М.В. Патогенетические механизмы развития фибрилляции предсердий при ожирении. Рациональная фармакотерапия в кардиологии. 2016; 12(5): 582-589. https://dx.doi.org/10.20996/1819-6446-2016-12-5-582-589.
  18. Goudis C.A., Korantzopoulos P., Ntalas I.V. et al. Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and links. J Cardiol. 2015; 66(5): 361-69. https://dx.doi.org/10.1016/j.jjcc.2015.04.002.
  19. Khan I.A. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001; 37(2): 542-47. https://dx.doi.org/10.1016/s0735-1097(00)01116-5.
  20. Heldal M., Atar D. Pharmacological conversion of recent-onset atrial fibrillation: A systematic review. Scand Cardiovasc J Suppl. 2013; 47(1): 2-10 https://dx.doi.org/10.3109/14017431.2012.740572.
  21. Подзолков В.И., Тарзиманова А.И. Пропафенон в лечении нарушений ритма сердца. Кардиология. 2012; 52(5): 70-73. EDN: PMXGET.
  22. Kochiadakis G.E., Igoumenidis N.E., Hamilos M.E. et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007; 99(12): 1721-25. https://dx.doi.org/10.1016/j.amjcard.2007.01.059.
  23. Andrade J.G., MacGillivray J., Macle L. et al. Clinical effectiveness of a systematic «pill-in-the-pocket» approach for the management of paroxysmal atrial fibrillation. Heart Rhythm. 2018; 15(1): 9-16. https://dx.doi.org/10.1016/j.hrthm.2017.10.002.
  24. Фомина И.Г., Тарзиманова А.И., Ветлужский А.В. с соавт. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. ПРОМЕТЕЙ - открытое, мультицентровое, пилотное исследование в Российской Федерации (часть II). Кардиоваскулярная терапия и профилактика. 2005; 4(5): 62-65. EDN: HWESHN.
  25. Миллер О.Н., Старичков С.А., Поздняков Ю.М. с соавт. Эффективность и безопасность применения пропафенона (Пропанорма®) и амиодарона (Кордарона®) у больных с фибрилляцией предсердий на фоне артериальной гипертонии, ишемической болезни сердца и хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка. Российский кардиологический журнал. 2010; 15(4): 55-71. EDN: MUENJV.
  26. Valembois L., Audureau E., Takeda A. et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019; 9(9): CD005049. https://dx.doi.org/10.1002/14651858.CD005049.pub5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies